Vertex plunks down $950M for stem cell player Semma by Amirah Al Idrus Tuesday, September 3, 2019 Vertex Pharmaceuticals is jumping into diabetes with a $950 million acquisition of Semma Therapeutics and its stem cell-based diabetes treatments.
Regenerating insulin-producing cells with zinc in diabetes by Angus Liu Friday, December 7, 2018 A team of Stanford University scientists has found a way to direct a regenerative diabetes medicine to the right cells more precisely.
Novo Nordisk steps up interest in diabetes stem cell therapies by Nick Paul Taylor Thursday, May 17, 2018 With the diabetes project moving to within a few years of the clinic, Novo is stepping up its interest in stem cell therapies more broadly.
Roivant licenses Ligand diabetes drug, founds Metavant by Nick Paul Taylor Wednesday, March 7, 2018 The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly minted cardiometabolic disease startup Metavant.
UnitedHealth puts Dexcom at center of diabetes management by Nick Paul Taylor Thursday, January 11, 2018 The initiative will provide certain UnitedHealth members with Dexcom’s CGM technology and personalized coaching to help manage their diabetes.
Metavention raises $65M to trial Type 2 diabetes treatment by Nick Paul Taylor Tuesday, January 9, 2018 The Minneapolis-based medtech firm is aiming to improve glucose control in diabetics by ablating nerves linked to metabolic organs.
Fractyl Labs ropes in $44M in series D funding by Emily Wasserman Friday, December 1, 2017 Fractyl plans to use the funds to develop its water-filled balloon device, Revita DMR.
News of Note—Attune Medical bags $10M; and more by Amirah Al Idrus Wednesday, October 18, 2017 Here's Wednesday's medtech news of note.
Merck pays $760M to buy into KalVista diabetes drug by Phil Taylor Tuesday, October 10, 2017 KalVista has been looking for a big pharma partner for its plasma kallikrein inhibitors, and just had its wish fulfilled by Merck & Co.
2. Johnson & Johnson by Amirah Al Idrus Johnson & Johnson started 2016 by cutting 3,000 jobs, part of a restructuring move to shore up its lagging medical device businesses. The cuts, in its orthopedics, surgery and cardiovascular units, made up 6% of its medical device employees.
